STOCK TITAN
  1. Home
  2. News
  3. QGEN

Qiagen NV - QGEN STOCK NEWS

Welcome to our dedicated news page for Qiagen NV (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Qiagen NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Qiagen NV's position in the market.

News
QIAGEN announces partnership with Penn State University to advance microbiome sciences
Rhea-AI Summary
QIAGEN (QGEN) announced a partnership with Penn State University to create a shared research and education facility for microbiome sciences. The collaboration aims to address challenges and research gaps facing the microbiome and will provide QIAGEN with a site to support the development of new products. The partnership will also offer industry research and training opportunities for next-generation scientists, including an internship program for graduate students at QIAGEN laboratories in Germany. The collaboration is anchored in a shared vision for an interconnection between the health of humans, animals, and ecosystems, and aims to accelerate the careers of scientists interested in the microbiome field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
partnership
-
News
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million
Rhea-AI Summary
QIAGEN N.V. announced a synthetic share repurchase plan to return up to approximately $300 million to shareholders through a direct capital repayment and a reverse stock split. The plan is expected to reduce the number of issued shares by approximately 3% and lead to a reduction of approximately 6.9 million shares. Shareholders will receive a capital repayment of $1.28 per pre-split share. The last day of trading of the pre-split shares is planned to be Monday, January 29, 2024, with the consolidated shares expected to begin trading on Tuesday, January 30, 2024. Technical details regarding settlement mechanics for shareholders holding their QIAGEN shares in brokerage accounts in the United States and in Germany and elsewhere in Europe are also provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
buyback
-
News
QIAGEN N.V. to release results for Q4 2023 and hold webcast
Rhea-AI Summary
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) plans to release results for the fourth quarter and full year 2023 on Tuesday, February 6, after 22:05 Frankfurt time. The conference call is scheduled for Wednesday, February 7, at 15:00 Frankfurt time. Investors and analysts can join the call through various options, including call back connection, dial-in by phone, and access to the audio webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
earnings
News
QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems
Rhea-AI Summary
QIAGEN (QGEN) receives FDA clearance for NeuMoDx CT/NG Assay 2.0, expanding its test menu for integrated PCR-based clinical molecular testing systems in the U.S. The assay is designed for direct detection of asymptomatic and symptomatic bacterial infections involving Chlamydia trachomatis (CT) and / or Neisseria gonorrhoeae (NG), the most common type of bacterial infection among sexually transmitted infections (STIs). This clearance supports the test menu expansion for NeuMoDx Molecular Systems in the U.S., complementing the broad menu offered in Europe and other countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
clinical trial
-
News
QIAGEN announces plans to return approximately $300 million to shareholders
Rhea-AI Summary
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced a plan to return up to $300 million to shareholders through a synthetic share repurchase, designed to enhance EPS and efficiently return cash to shareholders. The implementation is planned to be completed in late January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business
Rhea-AI Summary
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) plans to strengthen its market-leading QIAGEN Digital Insights (QDI) business by investing over the next five years to expand its offerings in new geographic regions and market segments, launch at least five new products, enhance existing products, and extend its augmented molecular intelligence approach with additional AI and NLP capabilities. The company aims to alleviate informatics bottlenecks for precision medicine and precision care insights, as well as to broaden its reach and boost market penetration for both existing and new products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
News
QIAGEN expands business in Middle East with new regional headquarters and major projects
Rhea-AI Summary
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region. The company signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to support public health initiatives and will also support Oman’s nationwide tuberculosis screening program for expatriates with hundreds of thousands of QuantiFERON-TB Gold Plus tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
News
DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy
Rhea-AI Summary
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DNA Labs International recently solved two cold cases in Oregon and Georgia using the ForenSeq Kintelligence System, highlighting the effectiveness of this new approach to human identification. The system enables identification of distant relatives in genealogy databases, bringing answers to victims and families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
News
QIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation
Rhea-AI Summary
QIAGEN (QGEN) Expands Sample Technologies Portfolio with TissueLyser III and RNeasy PowerMax Soil Pro Kit, offering efficient sample disruption and high-purity RNA isolation. The TissueLyser III enhances QIAGEN's high-throughput sample preparation, while the RNeasy PowerMax Soil Pro Kit utilizes advanced Inhibitor Removal Technology for challenging soil samples. The introduction of these products aims to better serve the unique needs of researchers working with difficult samples and enable a higher level of efficiency and accuracy in their work.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
News
QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers
Rhea-AI Summary
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launches three new QIAcuity kits for digital PCR applications in biopharma research and food safety, along with a major software update to streamline digital PCR analysis. The new kits offer precise quantification, increased sensitivity, and cost-efficiency, expanding the portfolio of applications for digital PCR technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
Stock QGEN logo
Qiagen NV

NYSE:QGEN

QGEN Rankings

#835 Ranked by Market Cap
#3158 Ranked by Stock Gains
N/A Ranked by Dividends

QGEN Stock Data

8.89B
219.34M
0.42%
74.25%
1.61%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Netherlands
Venlo

About QGEN

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.